Acneiform Eruptions Observed After Vemurafenib Treatment

Share this content:
Acneiform Eruptions Observed After Vemurafenib Treatment
Acneiform Eruptions Observed After Vemurafenib Treatment

MONDAY, Aug. 29, 2016 (HealthDay News) -- Acneiform eruptions due to the BRAF kinase inhibitor (BRAFi) vemurafenib in a patient with multiple metastatic melanoma lesions are described in a case report published online Aug. 11 in the Journal of Dermatology.

Osamu Ansai, from the Niigata University Graduate School of Medicine in Japan, and colleagues describe the case of a 54-year-old man with a history of malignant melanoma who underwent wide local excision and one year of β-interferon therapy. Multiple metastatic lesions were found on computed tomography three years later. As his tumor cells were BRAF V600E mutation positive, he started therapy with vemurafenib twice daily.

The authors note that the patient presented with painful and itchy erythemas and nodules with numerous comedones on his lower jaw within one week of starting therapy. Numerous well-circumscribed red papules and nodules increased and expanded to perioral, perinasal, and eyebrow, despite treatment with oral minocycline and topical hydrocortisone. Open and closed comedones surrounding acanthotic and intricate epidermal wall were seen on biopsy. Around the comedones, numerous lymphocytes and neutrophils infiltrated. No pathogenic bacteria and fungi were identified on culture of pustules on the face.

"Our report provides a crucial information to better understand cutaneous adverse events caused by BRAFi, and also suggests that retinoids can be effective in BRAFi-induced acneiform eruptions," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »